Schering AG And Agis To Be Sued

15 January 1996

The State of Israel is claiming NIS3 million (about $1 million) from German pharmaceutical company Schering AG and its Israeli representative Agis. The government-run Nuclear Research Center Nahal Soreq claims that the firms infringed an agreement, under which Schering would give to Nahal Soreq a license to manufacture a diagnostic product for the identification of cancer growths, with Agis as its exclusive marketer.

According to the petition, the defendants had objected to the marketing of the product, which Nahal Soreq had developed, on the grounds that it infringes patents held by Schering. In the petition letter, it is claimed that at end-1992, after long negotiations, Schering agreed to give the claimant a license to manufacture and market the product. The claimant was offered first preference to complete development and registration of the product, and invested considerable resources for this purpose.

The claimant alleges that in May 1993, after the Ministry of Health gave permission for the product's marketing, the defendants stated that they no longer intended to carry out their obligations, and furthermore, would sue Nahal Soreq for patent infringement if it tried to market the diagnostic. It is alleged that the defendants also threatened to flood the market with dump-price product.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight